With companies driving their own engagement and alternatives to journals becoming mainstream, does impact factor still matter?
This article addresses the metrics that Medical Affairs can use to measure how effectively they communicate on their strategic imperatives, with a specific focus on Share of Scientific Voice (SoSV).
The MAPS Puerto Rico Roundtable hosted by Real Chemistry in March 2024 discussed the integration of digital platforms, AI, and personalized content to enhance engagement with healthcare providers (HCPs). The panel emphasized the shift towards real-time, tailored information delivery and the importance of leveraging insights from both traditional and digital sources to support effective engagement strategies while ensuring compliance.
In this podcast, we discuss a data-driven approach for optimizing congress planning and execution.
Drawing on insights from a roundtable of industry leaders convened by Klick at the recent MAPS conference, let’s look at how viewing the KOL holistically can lead to new avenues of engagement and more multifaceted relationships.
In this podcast, we explore now that we appreciate the need to demonstrate impact and technologies exist that allow us to measure impact…what’s holding us back?
Addressing the critical importance of integrating robust scientific understanding into the commercial journey, pinpointing the need for medical affairs to take the helm in defining and communicating the commercial value of healthcare innovations.
From the choice of where to publish to the assessment of impact, every decision holds weight in medical research publication. And yet, the metrics that have been traditionally used to guide these decisions offer only a partial view. The result: a hit-or-miss situation when it comes to reaching the target audience—healthcare professionals (HCPs) and patients. Can a data-driven approach that incorporates both traditional and the newer alternative metrics hold the key to improved publication planning, impact and thereby better patient outcomes?
In this podcast, we explore the origins of negative opinions of the pharmaceutical industry, and whether a for-profit model can support both innovation and the society’s best interests.
In this podcast, we ask what is the ONE thing a company must implement in their transformation from the 40-slide deck to modern scientific storytelling.